CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
- 1 August 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (3) , 1070-1071
- https://doi.org/10.1182/blood-2002-11-3333
Abstract
CD20 has been reinvestigated in 66 patients with multiple myeloma (MM). Twelve of the patients (18%) expressed CD20, including 5 of 50 patients at diagnosis presenting 100% CD20+ cells. Seven (58%) of 12 CD20+ patients with MM had a small mature plasma cell morphology as opposed to 4 (7%) of 54 with CD20- MM ( P = .0001). Of note, 10 (83%) of 12 patients with CD20+ MM had t(11;14) as opposed to 5 of 54 (9%) CD20- patients ( P < .001). All the patients with 100% CD20+ cells presented with t(11;14) and 4 of 5 with a small mature plasma cell morphology. Thus, 66% of the patients with t(11;14) expressed CD20, whereas only 4% of the 51 patients lacking such translocation expressed CD20 ( P < .0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM.Keywords
This publication has 12 references indexed in Scilit:
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patientsBlood, 2002
- Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentationBlood, 2002
- CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic ApplicationsJournal of Immunotherapy, 2002
- The (11;14)(q13;q32) Translocation in Multiple MyelomaAmerican Journal of Clinical Pathology, 2000
- Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphologyLeukemia Research, 1999
- The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myelomaLeukemia, 1998
- Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cellsAnnals of Hematology, 1992
- Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the diseaseBritish Journal of Haematology, 1991
- Histologic Classification and Staging of Multiple Myeloma: A Retrospective and Prospective Study of 674 CasesAmerican Journal of Clinical Pathology, 1987